Analysts Set Agenus Inc. (NASDAQ:AGEN) Target Price at $31.00

Shares of Agenus Inc. (NASDAQ:AGEN) have been assigned a consensus recommendation of “Hold” from the six ratings firms that are covering the company, MarketBeat reports. Five analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $31.00.

Several research analysts recently commented on the stock. William Blair downgraded shares of Agenus from an “outperform” rating to a “market perform” rating in a research note on Thursday, July 18th. Baird R W downgraded shares of Agenus from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 19th. Jefferies Financial Group reissued a “hold” rating and set a $7.00 price objective (up from $3.00) on shares of Agenus in a research report on Friday, July 19th. Robert W. Baird downgraded shares of Agenus from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $35.00 to $8.00 in a research report on Friday, July 19th. Finally, HC Wainwright downgraded shares of Agenus from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $40.00 to $9.00 in a research report on Thursday, July 18th.

Agenus Stock Down 2.7 %

Shares of NASDAQ AGEN opened at $5.97 on Friday. Agenus has a 52 week low of $4.78 and a 52 week high of $32.00. The firm’s fifty day moving average is $13.98 and its 200 day moving average is $12.60. The company has a market cap of $125.27 million, a price-to-earnings ratio of -0.46 and a beta of 1.32.

Agenus (NASDAQ:AGEN) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($3.04) EPS for the quarter, topping the consensus estimate of ($3.58) by $0.54. The firm had revenue of $28.01 million during the quarter, compared to analysts’ expectations of $40.70 million. Equities research analysts anticipate that Agenus will post -10.73 earnings per share for the current year.

Institutional Trading of Agenus

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Hennion & Walsh Asset Management Inc. grew its position in shares of Agenus by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 558,606 shares of the biotechnology company’s stock worth $324,000 after buying an additional 13,604 shares during the period. PCG Wealth Advisors LLC boosted its stake in Agenus by 65.7% in the 4th quarter. PCG Wealth Advisors LLC now owns 47,550 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 18,850 shares in the last quarter. Values First Advisors Inc. boosted its stake in Agenus by 7.8% in the 4th quarter. Values First Advisors Inc. now owns 269,829 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 19,568 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in Agenus by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 107,019 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 27,137 shares in the last quarter. Finally, Crestline Management LP boosted its stake in Agenus by 6.5% in the 4th quarter. Crestline Management LP now owns 708,480 shares of the biotechnology company’s stock worth $587,000 after purchasing an additional 43,480 shares in the last quarter. 61.46% of the stock is owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.